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hundred and fifty one patients developed ESRD and there 
were 69 pre-ESRD deaths. The ARR model significantly strat-
ified the IgAN cohort according to risk of ESRD/death. The 
inclusion of eGFR and age significantly improved the ARR 
prognostic model; in the receiver operator characteristics 
(ROC) analysis, area under the curve (AUC) at 10-years of fol-
low-up increased from 0.79 to 0.89, p < 0.001.  Conclusions: 
ARR is a suitable prognostic model for stratifying IgAN pa-
tients according to the risk of ESRD or death. Including initial 
eGFR and age in the model substantially improved its accu-
racy in our nationwide cohort.  © 2015 S. Karger AG, Basel 
 Introduction 
 Immunoglobulin A nephropathy (IgAN) is general-
ly considered the most frequently occurring primary glo-
merulonephritis in the world  [1–3] , and prognostic aspects 
of the disease are of great interest for nephrologists and 
researchers. The clinical outcome of IgAN is variable, rang-
ing from minor and stable asymptomatic disease to pro-
gressive renal failure and end-stage renal disease (ESRD) 
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 Abstract 
 Background: Predicting outcome in individual patients with 
IgA nephropathy (IgAN) is difficult but important. For this 
purpose, the absolute renal risk (ARR) model has been devel-
oped in a French cohort to calculate the risk of end-stage 
renal disease (ESRD) and death. ARR (0–3) is scored in indi-
vidual IgAN patients based on the presence of proteinuria 
 ≥ 1  g/24 h, hypertension, and severe histopathological le-
sions (1 point per risk factor). We have validated the ARR 
model in a Norwegian cohort of IgAN patients and tested 
whether adding data on initial estimated glomerular filtra-
tion rate (eGFR) and age improved prediction.  Methods: 
IgAN patients diagnosed between 1988 and 2012 were iden-
tified in the Norwegian Kidney Biopsy Registry, and end-
points were identified by record linkage with the Norwegian 
Renal Registry (ESRD) and the Population Registry (deaths). 
 Results: We identified 1,134 IgAN patients. The mean dura-
tion of follow-up was 10.2 years (range 0.0 to 25.7 years). Two 
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 [4–6] . Identification of single risk factors in IgAN patients 
is valuable and has received considerable attention  [7–13] ; 
however, a combination of different risk factors is poten-
tially even more useful, and a few models incorporating 
multiple factors have been published in recent years  [4–6, 
14, 15] . A reliable and widely generally accepted prognos-
tic  model can aid the nephrologist when informing the 
 patient about the expected prognosis and deciding on fol-
low-up and treatment regimens. Furthermore, prognostic 
stratification is important when IgAN patients are includ-
ed in clinical studies and in the comparison of outcome in 
different IgAN cohorts. In a recent review, Barbour and 
Reich demonstrated that various prognostic models of 
IgAN have been developed in cohorts with considerable 
differences, for example, number of included patients, 
length of follow-up, and selection of endpoints and risk 
 factors are highly variable  [4] . In addition, to gain general 
acceptance, external validation of prognostic models is 
necessary before implementation in clinical practice  [16] .
 Recently, Berthoux et al. published the new prognostic 
absolute renal risk (ARR) model to predict ESRD or death 
in IgAN patients  [14] . This model is based on the pres-
ence or absence of hypertension, proteinuria  ≥ 1 g/24 h, 
and severe histopathological renal lesions. Based on these 
risk factors, IgAN patients are stratified into four catego-
ries with an ARR score from 0–3 points. This model is 
simple to use, and the primary endpoint of ESRD or death 
is highly clinically significant. Of note, a well-established 
risk factor in IgAN patients, initial estimated glomerular 
filtration rate (eGFR)  [4–6, 17] , is not included in this 
model. Neither is age, which is a very strong predictor for 
death and generally patients with chronic kidney disease 
(CKD) stage 3–5 consist of older patients than patients 
with CKD stage 1 or 2  [15, 20] .
 We have tested the validity of the ARR model in a 
 nationwide cohort of 1,134 IgAN patients from the 
 Norwegian Kidney Biopsy Registry with up to 25 years of 
follow-up. We hypothesized that ARR would be useful in 
the Norwegian IgAN cohort but that including initial 
eGFR and age in the model would further improve its ac-
curacy.
 Subjects and Methods 
 The study was approved by the Regional Ethics Committee.
 Registries Used in the Present Study 
 The Norwegian Kidney Biopsy Registry (NKBR) was estab-
lished in 1988 and has collected clinical, biochemical, immuno-
logical, and morphological data from most patients who have had 
a kidney biopsy performed in Norway (current population, 5.1 
million) since 1988. All kidney biopsies are evaluated by an expe-
rienced nephropathologist. The Norwegian Renal Registry is lo-
cated at Oslo University Hospital, Rikshospitalet, Norway. All pa-
tients in Norway starting chronic renal replacement therapy 
(chronic dialysis treatment or kidney transplant) have been regis-
tered since 1980. The Norwegian Population Registry is part of the 
tax office in Norway, all Norwegian citizens are registered with a 
unique 11-digit personal number, and all deaths are registered on 
a weekly basis.
 Identification of Patients with IgAN 
 We identified all patients diagnosed with primary IgAN and 
included in NKBR in the period from 1988–2012. The diagnosis of 
IgAN was based on the criteria described in a World Health Orga-
nization monograph of renal disease  [18] .
 Method of Follow-Up and Definition of Endpoint 
 The observation period was defined as the period between the 
date of the kidney biopsy and ESRD (commencement of renal re-
placement therapy in the form of maintenance dialysis treatment 
or kidney transplantation), death, or the end of June 2013, which-
ever came first. The primary endpoint of the present study was 
ESRD or death. ESRD and death were identified by record link-
ages of the study cohort with the Norwegian Renal Registry and 
the Norwegian Population Registry. Only deaths prior to the de-
velopment of ESRD were counted as endpoints in the present 
study. In separate analyses of risk of ESRD, death prior to ESRD 
was treated as a censoring event. In separate analyses of risk of pre-
ESRD death, ESRD was treated as a censoring event. We classified 
causes of death as cardiovascular disease, malignant disease, infec-
tious disease, or other disease/accident.
 Prognostic Factors Used in the Study 
 Proteinuria < vs.  ≥ 1 g/24 h . Proteinuria was measured quanti-
tatively in 80% of cases. In 16% of the patients proteinuria was 
semi-quantified with a standard urine dipstick with ( − ), (+), (++) 
and (+++) corresponding to <30, 30–99, 100–299 and  ≥ 300 mg/
dl of urine albumin  [19] . The result was converted as follows: 
 ≤ 1+ = <1 g/24 h and  ≥ 2+ =  ≥ 1 g/24 h  [17] . When neither quanti-
tative nor dipstick measurements were available (4% of patients), 
the notification of indication for biopsy on the Kidney Biopsy 
Registry report form was used. When the answer to the question 
‘proteinuria and nephrotic syndrome yes/no’ was ‘no’, proteinuria 
was set to <1 g/24 h; if the answer was ‘yes’, proteinuria was set to 
 ≥ 1 g/24 h.
 Hypertension . We defined hypertension as measured blood 
pressure (BP)  ≥ 140/90 mm Hg or use of antihypertensive treat-
ment; these data were available in 95% of the patients. In cases with 
missing data on blood pressure (<5%), the notification of indica-
tion for biopsy on the Kidney Biopsy Registry report form was used 
and based on the answer to the question ‘hypertension yes/no’.
 Histological Characteristics. We used a similar definition of 
mild or severe histopathological lesions as previously reported 
 [20] . Severe lesions were defined as follows: adhesions/segmental 
sclerosis/crescents/global sclerosis in more than 10% of the glom-
eruli OR interstitial inflammation/fibrosis in more than 25% of 
the biopsy area OR significant vasculopathy.
 Estimated GFR (eGFR). We used the Chronic Kidney Disease 
Epidemiology Collaboration formula (CKD-EPI) to calculate the 
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eGFR from serum creatinine. We stratified patients based on eGFR 
data into three groups:  ≥ 60, 30–60, and <30 ml/min/1.73 m 2 .
 Age. Patients were stratified according to age <60 vs.  ≥ 60 years.
 Scoring of Patients According to ARR 
 Patients were scored according to the number of risk factors 
(proteinuria  ≥ 1 g/24 h, hypertension, BP  ≥ 140/90, and severe path-
ological lesions; 1 point for each risk factor) into four risk groups 
(ARR score 0–3).
 Modified ARR Model 
 The modified ARR model is based upon the risk factors from 
the original ARR model (proteinuria, hypertension and severe his-
topathological lesions), and also including eGFR data divided into 
three groups:  ≥ 60, 30–60, and <30 ml/min/1.73 m 2 and age: <60 
vs.  ≥ 60 years. The importance or weight of each risk factor in the 
modified ARR model is derived from the adjusted Hazard Ratios 
(HR) estimated by a Cox proportional hazard model. The modi-
fied ARR score for each patient is calculated by multiplying the 
adjusted HR associated with each of the 5 risk factors if present, 
mathematical formula shown in online supplementary figure 1 
(www.karger.com/doi/10.1159/000381403). Example: For pro-
teinuria  ≥ 1 g/24 h and severe histopathological picture, we derived 
HR = 2.1 and 2.4, respectively. Consequently, a patient with these 
but no other risk factors present has a modified ARR score of 5.0 
(2.1 × 2.4).
 Furthermore, the study cohort was risk stratified into 6 groups 
using the log-transformed modified ARR score. Risk group A; log 
score = 0, group B; log score >0–<1, group C; log score  ≥ 1–<2, 
group D; log score  ≥ 2–<3, group E; log score  ≥ 3–<4 and group F; 
log score  ≥ 4–<5.
 Statistical Analyses 
 Statistical analyses were performed using the statistical soft-
ware SPSS Statistics 22 (SPSS Inc.). All statistical analyses were 
two-tailed, and a significance level of 0.05 was treated as statisti-
cally significant. First, we tested whether the Cox proportional 
hazard model fitted the data well and that the proportional hazard 
assumption was not violated. Second, we calculated the unadjust-
ed and adjusted HRs for ESRD or death for each prognostic com-
ponent in the ARR concept and for eGFR 30–60 and <30 ml/
min/1.73 m 2 and age  ≥ 60 years. Third, using Kaplan-Meier statis-
tics, we calculated the cumulative risk of ESRD or death after 5 and 
15 years of follow-up in each ARR group and modified ARR 
group. Log-rank tests were used to test statistical significance. 
Third, receiving operating characteristic (ROC) curves were used 
to evaluate the performance of the ARR and the modified ARR 
models. We derived ROC curves and calculated the area under the 
curve (AUC) for 5, 10, and 15 years survival excluding observa-
tions censored before 5 respectively 10 and 15 years follow-up. 
Fourth, we calculated the number of patients needed to follow 
(NNTF) in the different risk groups of the ARR and the modified 
ARR model. NNTF can be defined as how many patients are need-
ed to follow to detect one patient with endpoint. Fifth, we calcu-
lated the consequences of not following one or several low risk 
groups. Finally, we compared the French and Norwegian study 
cohorts regarding the distribution of patients in each ARR group 
and with initial eGFR <60 ml/min/1.73 m 2 . In the French cohort, 
time zero preceded the diagnostic biopsy with a mean of 5.5 years. 
Therefore and as further explained in the discussion section, cu-
mulative risks of dialysis/death 5 and 15 years after kidney biopsy 
were compared with 10 and 20 years outcome respectively in the 
French cohort.
 Results 
 We identified 1,134 IgAN patients. Of this cohort, 251 
(22%) developed ESRD, and 69 (6%) died prior to ESRD. 
Causes of death were cardiovascular disease (45%), ma-
lignant disease (16%), infectious disease (19%), or other 
disease/accident (20%). The mean duration of follow-up 
was 10.2 years (minimum 0.0, maximum 25.7 years). The 
mean age at time of IgAN diagnosis was 38 years (stan-
dard deviation, 16 years), and 73% of patients were males. 
Further cohort characteristics stratified for groups of 
baseline eGFR are shown in table 1.
 The Cox proportional hazard model fitted the data 
well, all risk factors were significant, and the proportion-
Table 1.  Cohort characteristics at the time of IgAN diagnosis stratified by the initial estimated glomerular filtra-
tion rate (eGFR)
Variable  Initial eGFR (ml/min/1.73 m2)
All
(n = 1,134)
≥60
(n = 702)
 30–59.9
(n = 264)
<30
(n = 168)
Mean (SD) age, years 38 (16) 32 (13) 45 (15) 53 (17)
Age ≥60 years 137 (12) 19 (3) 49 (19) 69 (41)
Male (%) 829 (73) 507 (72) 196 (74) 126 (75)
Proteinuria ≥1 g/24 h (%) 684 (60) 378 (54) 183 (69) 123 (73)
Hypertension (%) 411 (36) 170 (25) 132 (50) 107 (64)
Severe histopathological lesions (%) 749 (66) 374 (53) 220 (83) 155 (92)
 SD = Standard deviation.
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al hazard assumption did not seem to be violated. As also 
shown in table 2, adjusted HRs were as follows: protein-
uria  ≥ 1 g/24 h, 2.1; hypertension, 1.4; severe histopatho-
logical lesions, 2.4; eGFR 30–60 ml/min/1.73 m 2 , 3.7; 
eGFR <30 ml/min/1.73 m 2 , 11.3 and age  ≥ 60 years, 1.4.
 At 5 and 15 years of follow-up respectively, the cumu-
lative risk of ESRD or death was 3 and 6% with an ARR 
score of 0; 6 and 21% with an ARR score of 1; 17 and 43% 
with an ARR score of 2; and 39 and 60% with an ARR 
score of 3. These data, as well as data on cumulative risk 
of ESRD and death prior to ESRD separately, are shown 
in table 3a and  figure 1 .
 In the modified ARR model, the scores ranged from 
1.0 to 111.6. Stratification of the scores into six groups 
(A–F) equally spaced on a logarithmic scale is shown in 
table 3b.
 The cumulative risk of ESRD or death at 5 and 15 
years respectively was 1 and 3% in group A, 3 and 11% in 
group B, 8 and 25% in group C, 15 and 55% in group D, 
37 and 77% in group E, and 74 and 88% in group F. These 
data, as well as data on cumulative risk of ESRD and 
death prior to ESRD separately, are shown in table 3a and 
 figure 2 .
 In ROC analyses, AUC values at 5, 10, 15 years were 
0.76, 0.79, 0.80, respectively with the original ARR model 
and 0.88, 0.89, 0.88, respectively with the modified 
ARR model (score 1–111.6) in this cohort, the differences 
being highly statistically significant, p < 0.001 ( fig. 3 a–c). 
AUC in ROC analyses after stratification into the risk 
group A–F did not change.
 As shown in table 4, NNTF was 16.7 with ARR 0, 4.8 
with ARR 1, 2.3 with ARR 2 and 1.7 with ARR 3. In the 
modified ARR model, NNTF was 33.3 in risk group A, 9.1 
in group B, 4.0 in group C, 1.8 in group D, 1.3 in group E, 
and 1.2 in group F.
 The consequences of defining low risk groups as non-
specialist candidates for follow-up are shown in table 4. 
Applying the original ARR model, excluding group 0 
from follow-up results in 185 (16%) less patients and still 
96% of end-points detected. Excluding group 0 and 1 re-
sults in 499 (44%) fewer patients with detection rate of 
end-points of 78%. Applying the modified ARR model, 
excluding group A from follow-up results in 168 (15%) 
less patients with detection rate of end-points of 98%. Ex-
cluding group A and B results in 394 (35%) fewer patients 
to follow and detection rate of end-points of 91%.
 Table 5 provides a comparison of the French  [14] and 
Norwegian cohorts. The most important baseline differ-
ence was that the Norwegian cohort had more patients 
with initial eGFR <60 ml/min/1.73 m 2 (38 vs. 26%). In 
general, Norwegian patients also had higher ARR scores, 
50% having an ARR score of 2–3 vs. 34% in the French 
cohort. Five years after the kidney biopsy, the risks of 
ESRD/death were 2% (French) versus 3% (Norwegian) in 
patients with ARR 0, 2 vs. 6% with ARR 1, 7 vs. 17% 
with  ARR 2 and 29 vs. 39% with ARR 3. Fifteen years 
Table 2.  Unadjusted and adjusted* HR for ESRD or death for components of ARR, initial eGFR and age
Total
n (%)
ESRD/deaths 
n (%)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Proteinuria
<1 g/24 h 450 (40) 80 (18) 1.0 1.0
≥1 g/24 h 684 (60) 240 (35) 2.9 (2.2–3.7) 2.1 (1.6–2.7)
Not hypertension 723 (64) 141 (20) 1.0 1.0
Hypertension 411 (36) 179 (44) 2.9 (2.3–3.6) 1.4 (1.1–1.7)
No severe histopathological lesions 385 (34) 51 (13) 1.0 1.0
Severe histopathological lesions 749 (66) 269 (36) 5.2 (3.8–7.2) 2.4 (1.7–3.3)
eGFR, ml/min/1.73 m2
≥60 702 (62) 77 (11) 1.0 1.0
30–59.9 264 (23) 122 (46) 5.7 (4.3–7.6) 3.7 (2.8–5.1)
<30 168 (15) 121 (72) 18.7 (14.1–25.2) 11.3 (8.1–15.7)
Age, years
<60 997 (88) 233 (23) 1.0 1.0
≥60 137 (12) 87 (64) 4.6 (3.6–5.9) 1.4 (1.1–1.9)
 * Adjusted for all other risk factors (proteinuria, hypertension, severe pathological lesions, eGFR, and age 
≥60). CI = Confidence interval.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ite
ts
bi
bl
io
te
ke
t i
 B
er
ge
n 
   
   
   
   
   
   
   
 
19
8.
14
3.
54
.1
 - 
12
/2
1/
20
15
 1
:4
5:
47
 P
M
 Knoop   et al. Am J Nephrol 2015;41:210–219
DOI: 10.1159/000381403
214
 after  biopsy the numbers were 4% (French) versus 6% 
 (Norwegian) in patients with ARR 0, 9 vs. 21% with ARR 
1, 18 vs. 43% with ARR 2 and 64 vs. 60% with ARR 3.
 Discussion 
 The major findings in the present study are that ARR 
is suitable to predict ESRD and death in Norwegian IgAN 
patients, confirming the findings of Berthoux et al.  [14] , 
and that including initial eGFR and age in our study sig-
nificantly increases the accuracy of the model. The ROC 
analyses show that the original ARR model can be char-
acterized as a fair prognostic model, whereas the new 
modified ARR model improved the prognostic capacity 
in our cohort. We have also shown that all components 
of the ARR concept are independent risk factors for ESRD 
and death in our IgAN patients and probably should be 
included in any prognostic model of this disease.
 Our findings are not surprising given the facts that 
proteinuria, hypertension, initial eGFR, and histopatho-
logical lesions are the four best documented traditional 
risk markers for progression to ESRD  [4–6, 17] and death 
in IgAN patients  [21] . In principle, all prognostic models 
should be tested on populations that are independent of 
the cohort used to develop the models  [16] . To our knowl-
edge the ARR model has previously only been validated 
on one external cohort, 74 patients with Henoch-Schön-
leins purpura  [22] , and the results of the present study 
therefor substantially increases the generalizability of the 
Tabl e 3.
a Cumulative risk of the combined primary endpoint, ESRD and pre-ESRD death, in different ARR score groups, stratified by eGFR 
values
ARR
groups
Total, 
n
ESRD
or death, 
n (%)
ESRD, 
n (%)
Pre-ESRD
death, n (%)
Cumulative risk 
ESRD or death, %
Cumulative risk 
ESRD, %
Cumulative risk
pre-ESRD death,  %
5 years 15 years 5 years 15 years 5 years 15 years
Original
ARR
model
0 185 14 (8) 11 (6) 3 (2) 3 6 2 5 1 1
1 314 57 (18) 40 (13) 17 (5) 6 21 4 15 2 6
2 375 116 (31) 93 (25) 23 (6) 17 43 14 36 3 11
3 260 133 (51) 107 (41) 26 (10) 39 60 33 54 10 14
Modified
ARR
model*
A 168 6 (4) 6 (4) 0 (0) 1 3 1 3 0 0
B 226 23 (10) 20 (9) 3 (1) 3 11 3 10 0 1
C 318 54 (17) 43 (14) 21 (7) 8 25 6 21 2 5
D 169 65 (38) 48 (28) 10 (6) 15 55 10 47 5 15
E 134 79 (59) 57 (43) 18 (13) 37 77 29 66 12 32
F 119 93 (78) 77 (65) 17 (14) 74 88 66 82 23 31
 * Table 3b shows the stratification of cohort based on modified ARR model.
b Stratification of cohort based on modified ARR model
Risk group Modified ARR score log modified ARR score
A 1.0 >0–<1
B 1.4–2.4 ≥1–<2
C 2.9–7.3 ≥2–<3
D 7.8–18.6 ≥3–<4
E 22.1–53.2 ≥4–<5
F 57.0–111.6 >0–<1
* Modified ARR score can be calculated by multiplying the adjusted Hazard Ratios given in table 2.
Example: For proteinuria ≥1 g/24 h and severe histopathological picture we derived HR = 2.1 and 2.4, respectively. Consequently a 
patient with these but no other risk factors present has a modified ARR score of 5.0 (2.1 × 2.4).
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 Fig. 2.  a–c Kaplan-Meier plots showing cumulative risk of end-
stage renal disease (ESRD) or death in each risk group (ARR) in 
the modified ARR model ( a ), ESRD ( b ), and death ( c ). 
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 Fig. 1.  a–c Kaplan-Meier plots showing cumulative risk of end-
stage renal disease (ESRD) or death in each absolute risk group 
(ARR) in the original ARR model ( a ), ESRD ( b ), and death ( c ). 
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model. Obviously, the suggested modified ARR model in 
the present study needs independent validation in other 
cohorts and populations before it can be considered a val-
id prognostic model of IgAN.
 IgAN patients are typically characterized by a great 
heterogeneity in disease presentation and outcome. We 
have shown that patients with decreased eGFR at diagno-
sis usually have a relatively poor long-term prognosis. As 
shown in the NNTF analysis, the greatest variability in 
outcome is observed in patients with an initial normal 
eGFR; this group is therefore the most challenging re-
garding models for prognostic and therapeutic consider-
ations, and the need for specialist follow-up. Our NNTF 
data indicates that patients with CKD 1–2 and ARR score 
 Fig. 3.  a–c Receiver operator characteristic (ROC) curves compar-
ing the original ARR model and the modified ARR model at 5, 10, 
and 15 years at risk, respectively. 
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0–1 probably do not need specialist follow-up after the 
kidney biopsy. Two limitations deserve attention. First, it 
is unknown to what extent treatment and specialist fol-
low-up have contributed to the low risk of these patients. 
Second, as IgAN is mostly diagnosed in young patients 
even a follow-up of up to 15 years may be insufficient to 
draw conclusions about the life-time risk of ESRD in 
these patients.
 Cumulative risks of ESRD/death with ARR score 0 and 
3 were approximately similar in the Norwegian and the 
French cohorts. With an ARR score of 1 and 2, the risks 
were substantially higher in the Norwegian cohort. It is 
possible that a higher fraction of patients with eGFR <60 
ml/min/1.73 m 2 and ARR score 1 and 2 in the Norwegian 
cohort can explain this finding. A direct comparison was 
unfortunately not possible because cumulative risk in the 
Table 4.  Prognostic abilities of the original ARR model and modified ARR model and evaluation of the number 
and proportions needed to follow-up to detect an endpoint during the first 15 years of follow-up
Cohort Groups Total, 
n
ESRD 
or 
death, 
n
Cumulative 
risk of ESRD
or death
15 years, %
DR, 
%
Cohort, 
%
NNTF
Original
ARR
model
0 185 14 6 100 100 16.7
1 314 57 21 96 84 4.8
2 375 116 43 78 56 2.3
3 260 133 60 42 23 1.7
Modified
ARR
model*
A 168 6 3 100 100 33.3
B 226 23 11 98 85 9.1
C 318 54 25 91 65 4.0
D 169 65 55 74 37 1.8
E 134 79 77 54 22 1.3
F 119 93 88 29 10 1.2
 * Table 3b shows the stratification of cohort based on modified ARR model.
DR = Detection rate (i.e., the proportion (%) of detected cases of ESRD/death if all with at least this value were 
followed). Cohort (i.e., the proportion (%) of cohort needed to be followed up if all with at least this value were 
followed). NNTF (i.e., numbers needed to follow, how many patients are needed to be followed up to detect one 
patient with endpoint).
Table 5.  Comparison of baseline characteristics and cumulative risk of the combined endpoint of ESRD/death 
between the French [reference] and Norwegian IgAN cohorts
 % of patients Cumulative risk of ESRD/death after kidney biopsy
French Nor wegian 5 (10)-year* 15 (20)-year*
French Norwegian French Norwegian
ARR = 0 46 19 2 3 4 6
ARR = 1 21 30 2 6 9 21
ARR = 2 20 27 7 17 18 43
ARR = 3 14 23 29 39 64 60
Initial eGFR <60 26 38
 * In the French study, time zero was the onset time of the disease, a date that preceded the diagnostic biopsy 
with a mean of 5.5 years. In the Norwegian cohort time, zero was the date the diagnostic kidney biopsy was per-
formed. As a result, we have compared 5 and 15 years outcome in the Norwegian with 10 and 20 years outcome 
in the French cohort.
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French study separately for different strata of initial eGFR 
was not reported.
 We must emphasize that we were not able to validate 
all aspects of the ARR prognostic model due to the nature 
of our database. First, in the French study time zero was 
onset of the disease, a date that preceded the diagnostic 
biopsy with a mean of 5.5 years. In the Norwegian cohort 
time, zero was the date the diagnostic kidney biopsy was 
performed. As a result, we have compared 5 and 15 years 
outcome in the Norwegian with 10 and 20 years outcome 
in the French cohort. Second, the definition of severe his-
topathological lesions is different between the studies. 
Due to data registration in the NKBR it was not possible 
to apply the global optical score (GOS) that is used in the 
French study. However, the same histological parameters 
(glomerular, vascular, and tubulointerstitial) are used in 
both GOS and the histological grading system of the pres-
ent study and the difference is thus probably relatively 
limited. Finally, the definition of proteinuria  ≥ 1 g/24 h 
was based on urine dipstick test or clinical information in 
20% of the Norwegian patients; in the French study, all 
patients had quantitatively measured proteinuria. Apart 
from these corrections, we consider our study as a strong 
external validation of the ARR prognostic model as de-
scribed by Berthoux et al.  [17]. 
 In the French study, progression to Chronic Kidney 
Disease (CKD) 3 or higher is an additional end-point to 
ESRD/death and therefore, it could not also serve as a risk 
factor in the ARR model. We could not apply CKD 3+ as 
an end point in our study because there are no follow-up 
data on kidney function in the NKBR database. Consider-
ing the complete biological course of IgAN, we agree with 
Berthoux et al. that a low initial eGFR is in fact a damage 
marker that suits as an end-point and not a risk factor of 
this disease. However, since IgAN initially often is an as-
ymptomatic condition, it is frequently not detected clini-
cally until late in the natural disease course. Thus, lead 
time bias is obviously a complicating factor in the assess-
ment of prognosis in IgAN patients. Nevertheless, in clin-
ical practice and as shown in the present study, a low 
eGFR at the time of the diagnostic kidney biopsy is an 
important prognostic marker regarding the future risk of 
ESRD/death.
 In contrast to another recently published prognostic 
model on IgAN patients  [17] , deaths occurring before the 
commencement of renal replacement therapy were in-
cluded in the current study as a primary endpoint in the 
ARR model. The rationale was the high mortality rate ob-
served in chronic kidney disease patients in general  [15] ; 
surprisingly, the same picture is not observed in patients 
with chronic kidney disease resulting from IgAN. In both 
the French and the current cohorts, cases of ESRD great-
ly outnumbered deaths. In the French study, 32 ESRD 
and 13 deaths  [14] were observed, compared to 251 ESRD 
and 69 deaths as observed in the present work. Further-
more, our group recently demonstrated that the mortal-
ity rate of IgAN patients with initial eGFR in the normal 
range is not increased compared to the general popula-
tion adjusted for age and sex  [21] . Thus, it may be disput-
able whether including deaths as an endpoint in the ARR 
model is appropriate, particularly when applied for pa-
tients with eGFR  ≥ 60 ml/min/1.73 m 2 .
 In addition to improved prognostic capacity, the mod-
ified ARR score also has other advantages compared to the 
original ARR model. For example, a patient with protein-
uria  ≥ 1 g/24 h and an aggressive histological picture but 
no other risk factors has a modified ARR score of 5.0 
(2.1 × 2.4). The hazard value for this person is 5.0 times 
the hazard value for a person with none of the risk factor 
apparent. Furthermore, the hazard value for a person with 
a score of 5.0 is 1.7 (5.0/2.9 = 1.7) times the hazard value 
for a patient who has a score of 2.9. With the original ARR 
model, the score (0–3) does not contain direct relative risk 
information. In total, there are 48 possible scores with the 
modified ARR model; some practitioners might find it 
useful to stratify the patients into fewer risk groups. We 
therefore also stratified the modified ARR scores into six 
groups equally spaced on a logarithmic scale.
 The obvious strength of our study is the large popula-
tion-based patient cohort with very long follow-up time 
and many endpoints. A weakness is the lack of informa-
tion regarding how the patients were treated; such infor-
mation is not available in the NKBR. In the French co-
hort, all patients were reported to have received adequate 
treatment; this is likely the case also in Norway since ne-
phrologists in general oversee the follow-up of IgAN pa-
tients. There are, however, no clear guidelines on treat-
ment of high-risk IgAN patients and differences in treat-
ment protocols are therefore likely. It is also a weakness 
of both the present and the French study that the Oxford 
classification of IgAN  [23] was not used to define severe 
histological lesions. It must, however, be noted that most 
patients in both studies were diagnosed prior to the pub-
lication of the Oxford classification and retrospective use 
of this classification on registry data is not feasible. Sec-
ond, there is obviously substantial overlap between the 
Global Optical Score (GOS), the definition of severe his-
tological lesions in the present study and the Oxford clas-
sification. Third, the Oxford Classification of IgAN was 
not developed for IgAN patients with low-grade protein-
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uria nor for patients with advanced kidney failure (eGFR 
<30 ml/min/1.73 m 2 ).
 Receiving operating characteristic (ROC) curves were 
used to evaluate the performance of the modified ARR 
score resulting in improved AUC values indicating that 
the model has a strong potential as a prognostic model for 
5–15 years survival. Note however that the derived AUC 
is subject to being overly optimistic because it is derived 
from the same data as was used to fit the Cox model.
 Time has perhaps come to suggest that there is a need 
for collaborative efforts aiming at developing a single and 
internationally accepted prognostic model incorporating 
both histological and clinical risk factors of this disease.
 In summary, we have shown that the ARR model is 
applicable to predict prognosis regarding the risk of ESRD 
and deaths in a Norwegian IgAN cohort. Inclusion of 
eGFR and age at time of diagnosis substantially improves 
the accuracy of the model, and may reduce the cost of un-
necessary specialist follow-up of low-risk patients. Ex-
cluding deaths as an endpoint should be considered when 
the ARR model is applied on IgAN patients with normal 
initial eGFR.
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